Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation

Nature Medicine

Volumn 24, Issue 1, 2018, Pages 29-38

  He, Zhuohao ^a   Guo, Jing L ^a   McBride, Jennifer D ^a   Narasimhan, Sneha ^a   Kim, Hyesung ^a   Changolkar, Lakshmi ^a   Zhang, Bin ^a   Gathagan, Ronald J ^a   Yue, Cuiyong ^b   Dengler, Christopher ^b   Stieber, Anna ^a   Nitla, Magdalena ^a   Coulter, Douglas A ^a,b   Abel, Ted ^c   Brunden, Kurt R ^a   Trojanowski, John Q ^a   Lee, Virginia M Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CELL FUNCTION; CONTROLLED STUDY; DYSTROPHY; FEMALE; GENE AMPLIFICATION; MICROENVIRONMENT; MOUSE; NEURITE; NEUROFIBRILLARY TANGLE; NEUROPIL THREAD; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; SENILE PLAQUE; TAUOPATHY; ANIMAL; AXON; HIPPOCAMPUS; HUMAN; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AXONS; HIPPOCAMPUS; HUMANS; MICE; NEURITES; NEUROFIBRILLARY TANGLES; TAU PROTEINS;

EID: 85040329978     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4443     Document Type: Article

References (39)

1. Hardy, J. A. & Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185 (1992).
2. Gómez-Isla, T. et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41, 17-24 (1997).
3. Bennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L. & Arnold, S. E. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch. Neurol. 61, 378-384 (2004).
4. Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960-969 (2011).
5. Schöll, M. et al. PET imaging of tau deposition in the aging human brain. Neuron 89, 971-982 (2016).
6. Schwarz, A. J. et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 139, 1539-1550 (2016).
7. Sepulcre, J. et al. In vivo tau, amyloid, and gray matter profiles in the aging brain. J. Neurosci. 36, 7364-7374 (2016).
8. Brier, M. R. et al. Tau and Aimaging, CSF measures, and cognition in Alzheimer's disease. Sci. Transl. Med. 8, 338ra66 (2016).
9. Wang, L. et al. Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between amyloid and tauopathy. JAMA Neurol. 73, 1070-1077 (2016).
10. Götz, J., Chen, F., van Dorpe, J. & Nitsch, R. M. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A42 fibrils. Science 293, 1491-1495 (2001).
11. Lewis, J. et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491 (2001).
12. Bolmont, T. et al. Induction of tau pathology by intracerebral infusion of amyloid-containing brain extract and by amyloid-deposition in APP × Tau transgenic mice. Am. J. Pathol. 171, 2012-2020 (2007).
13. Clavaguera, F. et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909-913 (2009).
14. Hurtado, D. E. et al. Aaccelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am. J. Pathol. 177, 1977-1988 (2010).
15. Pooler, A. M. et al. Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease. Acta Neuropathol. Commun. 3, 14 (2015).
16. Bennett, R. E. et al. Enhanced tau aggregation in the presence of amyloid. Am. J. Pathol. 187, 1601-1612 (2017).
17. Guo, J. L. et al. Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice. J. Exp. Med. 213, 2635-2654 (2016).
18. Saito, T. et al. Single App knock-in mouse models of Alzheimer's disease. Nat. Neurosci. 17, 661-663 (2014).
19. Nelson, P. T., Braak, H. & Markesbery, W. R. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J. Neuropathol. Exp. Neurol. 68, 1-14 (2009).
20. Mann, D. M. & Esiri, M. M. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J. Neurol. Sci. 89, 169-179 (1989).
21. Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755-766 (2014).
22. Oakley, H. et al. Intraneuronal amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140 (2006).
23. Sadleir, K. R. et al. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Ageneration in Alzheimer's disease. Acta Neuropathol. 132, 235-256 (2016).
24. Montine, T. J. et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 123, 1-11 (2012).
25. Bannerman, D. M. et al. Regional dissociations within the hippocampus-memory and anxiety. Neurosci. Biobehav. Rev. 28, 273-283 (2004).
26. Wang, Y. et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213, 667-675 (2016).
27. Yuan, P. et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90, 724-739 (2016).
28. Meyer-Luehmann, M. et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat. Neurosci. 6, 370-377 (2003).
29. Meyer-Luehmann, M. et al. Exogenous induction of cerebral amyloidogenesis is governed by agent and host. Science 313, 1781-1784 (2006).
30. Eisele, Y. S. et al. Peripherally applied A-containing inoculates induce cerebral amyloidosis. Science 330, 980-982 (2010).
31. Langer, F. et al. Soluble Aseeds are potent inducers of cerebral amyloid deposition. J. Neurosci. 31, 14488-14495 (2011).
32. Rosen, R. F. et al. Exogenous seeding of cerebral amyloid deposition in aPPtransgenic rats. J. Neurochem. 120, 660-666 (2012).
33. Almeida, C. G., Takahashi, R. H. & Gouras, G. K. amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J. Neurosci. 26, 4277-4288 (2006).
34. Montine, T. J. et al. Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease. Alzheimers Dement. 12, 164-169 (2016).
35. Li, W. & Lee, V. M. Characterization of two VQIXXK motifs for tau fibrillization in vitro. Biochemistry 45, 15692-15701 (2006).
36. Iba, M. et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J. Neurosci. 33, 1024-1037 (2013).
37. Guo, J. L. & Lee, V. M. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 286, 15317-15331 (2011).
38. Lee, E. B., Skovronsky, D. M., Abtahian, F., Doms, R. W. & Lee, V. M. Secretion and intracellular generation of truncated Ain site amyloid-precursor protein-cleaving enzyme expressing human neurons. J. Biol. Chem. 278, 4458-4466 (2003).
39. King, D. L. & Arendash, G. W. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol. Behav. 75, 627-642 (2002).